This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saffitz, J. E. Search for Related Content PubMed PubMed Citation Articles by Saffitz, J. E. Related Collections Clinical genetics Ion channels/membrane transport Myocardial cardiomyopathy disease Genetics of cardiovascular disease

(Circulation. 2005;112:3672-3674.)
© 2005 American Heart Association, Inc.

Editorial

Structural Heart Disease, SCN5A Gene Mutations, and Brugada Syndrome

A Complex Ménage à Trois

Jeffrey E. Saffitz, MD, PhD

From the Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass.

Correspondence to Jeffrey E. Saffitz, MD, PhD, Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215. E-mail jsaffitz@bidmc.harvard.edu

Key Words: Editorials • Brugada syndrome • cardiovascular diseases • ion channels • pathology

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The report of the Second Consensus Conference, published in Circulation in 2005, defined the Brugada syndrome as ST-segment elevation in the right precordial ECG leads (so-called type 1 ECG) and a high incidence of sudden death in patients with structurally normal hearts.¹ An autosomal dominant disease with incomplete penetrance, Brugada syndrome has been linked to mutations in SCN5A, the gene encoding the alpha subunit of the cardiac sodium channel.² More than 80 mutations in SCN5A have been linked to this syndrome (references cited in Reference 1). Analysis of several of these mutations has consistently demonstrated a loss of function related to multiple mechanisms, including failure of sodium channel protein expression and changes in the voltage and time dependence of sodium channel current activation, inactivation, or reactivation.¹ Still, SCN5A mutations have been reported in only &20% of patients with Brugada syndrome diagnosed on the basis of clinical criteria, suggesting that other genetic defects and/or other disease mechanisms may give rise to this clinical picture. To complicate matters further, SCN5A mutations have also been identified in patients with the long-QT syndrome. These mutations generally lead to a "gain of function" in the sodium channel, which prolongs the QT interval by increasing inward current. In fact, at least 3 human diseases have been linked to defects in this gene: Brugada syndrome, long-QT syndrome, and progressive conduction disturbances.^2–4 Furthermore, there is considerable overlap of clinical profiles, so some patients with Brugada syndrome also have atrial fibrillation, conduction defects with sinus node abnormalities, or . . . [Full Text of this Article]

This article has been cited by other articles:

				O. Catalano, S. Antonaci, G. Moro, M. Mussida, M. Frascaroli, M. Baldi, F. Cobelli, P. Baiardi, J. Nastoli, R. Bloise, et al. Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities Eur. Heart J., September 2, 2009; 30(18): 2241 - 2248. [Abstract] [Full Text] [PDF]